NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Shorla Oncology

Shorla Oncology

Private
ClonmelHealthcare & Life Scienceshttps://shorlaoncology.com/

Last Round

VC Round

Jan 17, 2026

Total Funding Raised

$43.3M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Shorla Oncology is a pharmaceutical company that develops and commercializes innovative oncology drugs, with a focus on orphan and pediatric cancers where existing treatments are limited or in short supply.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

specialty pharmaceuticalsoncology drugsorphan drugspediatric oncologydrug reformulation505(b)(2) pathwaydrug shortage solutionspharmaceutical repurposingready-to-use oncologyniche pharmadrug delivery innovationhospital pharmacy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shorla Oncology Comparables

Compare Shorla Oncology with similar companies based on industry and business-model similarity.

Shorla Oncology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Eagle Pharmaceuticals, Inc.
78%
Amneal Pharmaceuticals, Inc.
70%
Therakind Ltd
68%

Shorla Oncology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJan 17, 2026
Series BOct 4, 2023
Series AJun 3, 2020

Key People

Founding team and executive leadership

Orlaith Ryan

Chief Technical Officer, Co-Founder

Founding Team

Sharon Cunningham

CEO Co-Founder

Founding Team

Shorla Oncology Investors

Notable investors and investment history

Shorla Oncology investors
InvestorRounds
Seroba Life SciencesSeries B, VC Round, Series A
Enterprise IrelandSeries B, VC Round, Series A
Kurma PartnersSeries B, VC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 19, 2026

    Monthly visitors increased 41% MoM, from 1.8K to 2.6K.

  • Jan 27, 2026

    $21M round completed.

Shorla Oncology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shorla Oncology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shorla Oncology's valuation, stock price, and market status.

Firmographic Details

HeadquartersClonmel
Employee Range42
Year Founded2018
Last FundingJan 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.